Anti-ADAMTS-5 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody targeting the carboxyterminal region of ADAMTS-5, validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan, Monkey, Dog
UniProt
Q9UNA0
Size
100ug
Cat. #
RP1ADAMTS5

In stock

SKU
RP-ADAMTS5

Options

As low as: $130.00

Target Overview

A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5, UniProt Q9UNA0) is a secreted metalloproteinase belonging to the ADAMTS family of extracellular matrix (ECM) degrading enzymes. ADAMTS-5 functions as a major aggrecanase (aggrecanase-2), cleaving hyalectan chondroitin sulfate proteoglycans including aggrecan (ACAN), versican (VCAN), brevican (BCAN), and neurocan (NCAN) at specific Glu-Xaa recognition motifs. The 930-amino acid enzyme localizes to the extracellular matrix where it plays essential roles in connective tissue organization, embryonic development, and inflammation. Beyond cartilage degradation, ADAMTS-5 participates in skeletal muscle development through VCAN remodeling in the pericellular matrix, facilitating myoblast contact and fusion. The enzyme also contributes to brown adipose tissue development, white adipose tissue browning, and T-lymphocyte migration from draining lymph nodes following viral infection. Its proteolytic activity toward aggrecan makes ADAMTS-5 a key mediator in osteoarthritis pathogenesis and a target of significant research interest in connective tissue disorders.

Background

ADAMTS-5 has emerged as a central mediator in osteoarthritis progression, where its aggrecanase activity drives irreversible cartilage degradation. Unlike ADAMTS-4 (aggrecanase-1), ADAMTS-5 appears to be the dominant aggrecanase in murine models of cartilage destruction, though both enzymes contribute to human disease. The enzyme cleaves aggrecan within the interglobular domain, releasing glycosaminoglycan-rich fragments and compromising the biomechanical properties of articular cartilage. Recent work has explored upstream regulators of ADAMTS-5 expression in chondrocytes, including the role of TRIM62 in promoting chondrocyte ferroptosis and osteoarthritis progression, and the protective effects of fucoxanthin through JAK2/STAT3 pathway modulation (Adam et al., 2026). Beyond osteoarthritis, ADAMTS-5 participates in developmental processes including limb and cardiac morphogenesis. During skeletal muscle development and regeneration, ADAMTS-5 cleaves versican in the pericellular matrix surrounding myoblasts, a process required for proper myoblast fusion. The enzyme's substrate repertoire extends to multiple chondroitin sulfate proteoglycans, with cleavage specificity determined by Glu-Xaa motifs within the substrate sequence. Investigators studying ECM remodeling, inflammation, and tissue development have utilized ADAMTS-5 antibodies to monitor enzyme expression and localization across diverse experimental systems. Four rabbit polyclonal antibodies raised against the carboxyterminal region are available, validated in human samples by Western blot, with predicted cross-reactivity in mouse, rat, non-human primate, and canine tissues.

References

  1. Adam MS et al (2026) Fucoxanthin alleviates chondrocyte inflammation and osteoarthritis by modulating the JAK2/STAT3 signaling pathway. Mol Med Rep. PubMed · doi:10.3892/mmr.2026.13933
  2. Chen X (2026) TRIM62 promotes osteoarthritis progression by facilitating GPX4 ubiquitination and chondrocyte ferroptosis. Am J Transl Res. PubMed · doi:10.62347/DKML5977
  3. Jiang X et al (2026) Astragalus Polysaccharides Attenuate LPS-Induced Degenerative Responses in Primary Rat Chondrocytes linked to the NLRP3/CASPASE-1 Axis. J Musculoskelet Neuronal Interact. PubMed · doi:10.22540/JMNI-26-301
  4. Feng R et al (2026) Integrating network toxicology, molecular docking and experimental validation reveals potential mechanisms of DEHP in osteoarthritis. Exp Gerontol. PubMed · doi:10.1016/j.exger.2026.113198
  5. Chen C et al (2026) Lesion Site-Targeted Microspheres Modulate Nav1.7-Related Signaling for Osteoarthritis Treatment. Adv Sci (Weinh). PubMed · doi:10.1002/advs.75986

Additional Specifications

Gene Symbol ADAMTS5
UniProt ID Q9UNA0
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan, Monkey, Dog
Pack Size 100ug
Immunogen (Carboxyterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 880-930.
Immunogen (Aminoterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 262-312.
Immunogen (Propeptide domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 17-261.
Immunogen (Metalloproteinase domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 267-476.
Alternate Names A disintegrin and metalloproteinase with thrombospondin motifs 5, ADAM-TS 5, ADAM-TS5, ADAMTS-5, A disintegrin and metalloproteinase with thrombospondin motifs 11, ADAM-TS 11, ADAMTS-11, ADMP-2, Aggrecanase-2, EC 3.4.24.-

Frequently Asked Questions

What molecular weight should I expect for ADAMTS-5 on a Western blot?

Full-length ADAMTS-5 runs at approximately 100-120 kDa on reducing SDS-PAGE, though the predicted molecular weight from the 930-amino acid sequence is around 100 kDa. You may observe additional bands corresponding to proteolytic processing products, particularly fragments retaining the catalytic domain. ADAMTS-5 undergoes furin-mediated cleavage and autocatalytic processing in vivo, generating N-terminal fragments that retain enzymatic activity. Glycosylation also contributes to the apparent molecular weight heterogeneity. If working with conditioned media or extracellular matrix preparations, expect to see processed forms alongside the full-length enzyme.

What starting dilution should I use for Western blot with this ADAMTS-5 antibody?

We recommend starting at 1:1000 dilution for Western blot applications. This dilution has been validated with human samples and typically provides clean signal with low background when using standard chemiluminescent detection. If signal is weak in your system—particularly if ADAMTS-5 expression is low or you are working with conditioned media where the protein is dilute—you can increase concentration to 1:500. Conversely, if background is high, titrate up to 1:2000. Always include a positive control lysate from chondrocytes or osteoarthritic cartilage where ADAMTS-5 is abundantly expressed.

Will this antibody work with mouse and rat samples?

Cross-reactivity with mouse and rat ADAMTS-5 is predicted based on sequence homology but has not been experimentally validated by us. Human and mouse ADAMTS-5 share approximately 89 percent sequence identity, and rat homology is similar, suggesting the antibody should recognize these orthologs. However, we recommend validating performance in your specific system before committing to large-scale experiments. Test a dilution series starting at 1:1000 and include a known positive control such as murine chondrocyte lysate or cartilage explant extract to confirm reactivity and determine optimal working concentration.

Is this antibody suitable for detecting ADAMTS-5 in cartilage tissue sections?

Yes, This antibody is validated for Western blot; immunohistochemistry/immunofluorescence validation is in progress and should detect ADAMTS-5 in cartilage sections. ADAMTS-5 localizes to the extracellular matrix, particularly the pericellular and territorial regions surrounding chondrocytes in articular cartilage. For IHC, antigen retrieval is typically required—heat-induced epitope retrieval in citrate buffer (pH 6.0) works well for cartilage. Expression is notably elevated in osteoarthritic cartilage compared to healthy tissue, making OA samples useful positive controls. Be aware that ADAMTS-5 may appear as diffuse extracellular staining rather than discrete cellular localization due to its secreted nature and matrix association.

What positive control should I use to validate ADAMTS-5 detection?

Human chondrocyte lysates or osteoarthritic cartilage extracts serve as excellent positive controls, as ADAMTS-5 is abundantly expressed in cartilage and upregulated in osteoarthritis. Alternatively, use lysates from cells stimulated with interleukin-1β or tumor necrosis factor-α, which induce ADAMTS-5 expression in chondrocytes and synovial fibroblasts. For extracellular experiments, concentrated conditioned medium from stimulated chondrocytes contains secreted ADAMTS-5. SW1353 chondrosarcoma cells also express detectable ADAMTS-5. If working with other tissues, skeletal muscle or aortic smooth muscle extracts may provide positive signal, as ADAMTS-5 participates in versican remodeling in these contexts.

Does this antibody recognize both pro-ADAMTS-5 and the active processed form?

The epitope specificity has not been mapped to distinguish between pro-enzyme and processed forms. Given that this is a polyclonal antibody, it likely recognizes multiple epitopes across the ADAMTS-5 protein and should detect both the zymogen and proteolytically activated forms, provided the epitopes remain intact after processing. ADAMTS-5 undergoes furin cleavage to remove the prodomain, and subsequent autocatalytic processing can generate additional fragments. If your research requires discriminating between these forms, perform Western blots under reducing conditions and examine the banding pattern—full-length pro-ADAMTS-5, mature enzyme, and processed fragments will migrate differently based on molecular weight.

Can I use this antibody to detect ADAMTS-5 in conditioned cell culture media?

Yes, ADAMTS-5 is a secreted metalloproteinase, and this antibody should detect it in conditioned media by Western blot. Concentrate the media 10- to 20-fold using centrifugal filters (30 kDa cutoff) to improve detection, as secreted levels can be low depending on cell type and culture conditions. Include protease inhibitors during collection—EDTA or 1,10-phenanthroline to inhibit metalloproteinases that might degrade ADAMTS-5. Serum-free or low-serum conditions reduce background and avoid interference from serum proteases. Load equivalent cell numbers or volumes, and include unconditioned medium as a negative control to confirm signal specificity.

How should I store this antibody and how long will it remain stable?

Store the antibody at -20°C in single-use aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. Aliquot immediately upon receipt if you plan infrequent use—20 to 25 µL aliquots work well for most Western blot applications at 1:1000 dilution. The antibody remains stable for at least 12 months at -20°C when stored properly. For short-term use (up to one month), the working aliquot can be kept at 4°C with 0.02 to 0.05 percent sodium azide as preservative. Avoid storing diluted antibody; prepare working dilutions fresh in blocking buffer for each experiment.

Western blot validation for RP-ADAMTS5 — 2 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

ADAMTS-5: Propeptide domain — WB validation
WB · Panel 1 ADAMTS-5: Propeptide domain
ADAMTS-5: Metalloproteinase domain — WB validation
WB · Panel 2 ADAMTS-5: Metalloproteinase domain

Custom validation studies available on request — contact us.

Also known as:

  • A disintegrin and metalloproteinase with thrombospondin motifs 5
  • ADAM-TS 5
  • ADAM-TS5
  • ADAMTS-5
  • A disintegrin and metalloproteinase with thrombospondin motifs 11
  • ADAM-TS 11
  • ADAMTS-11
  • ADMP-2
  • Aggrecanase-2
  • EC 3.4.24.-
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →